In ₹ Crore except Per Share Latest Annual | WOCKPHARMA FY26 | BIOCON FY26 | SYNGENE FY26 | ASTERDM FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 169.20× | 138.65× | ◆ 48.79× | 101.99× | 101.99× +66% | |
| P/B | 6.81× | ◆ 1.73× | 3.20× | 8.23× | 3.20× +113% | |
| EV/EBITDA | 57.45× | 21.73× | ◆ 16.11× | 44.68× | 21.73× +164% | |
| Market Cap | ₹35,962 Cr | ₹63,381 Cr | ₹15,471 Cr | ₹39,790 Cr | ₹39,790 Cr -10% | |
| Growth | ||||||
| Revenue CAGR 3Y | 8.36% | ◆ 14.85% | 5.40% | -26.99% | 5.40% +55% | |
| Revenue CAGR 5Y | 4.49% | ◆ 18.96% | 11.35% | -11.61% | 11.35% -60% | |
| Net Income CAGR 3Y | — | -16.91% | -11.98% | ◆ -3.51% | -11.98% | |
| Revenue YoY (latest Q) | ◆ 25.88% | 10.00% | -15.84% | 21.60% | 10.00% +159% | |
| Net Income YoY (latest Q) | ◆ 199.07% | 53.36% | -110.38% | -68.70% | -68.70% +390% | |
| Profitability | ||||||
| EBITDA Margin | 19.33% | 20.41% | ◆ 24.57% | 19.41% | 20.41% -5% | |
| Net Income Margin | 5.90% | 2.18% | 8.47% | ◆ 9.20% | 8.47% -30% | |
| Return on Common Equity | 4.03% | 1.05% | 6.54% | ◆ 8.03% | 6.54% -38% | |
| Return on Capital Employed | 6.08% | 3.02% | 8.46% | ◆ 8.93% | 8.46% -28% | |
| Return on Assets | 2.31% | 0.58% | 4.49% | ◆ 5.27% | 4.49% -49% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.40× | 0.40× | ◆ 0.00× | 0.15× | 0.15× +167% | |
| Interest Coverage | 2.00× | 1.51× | ◆ 9.54× | 5.18× | 5.18× -61% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹3,373 Cr | ₹16,927 Cr | ₹3,739 Cr | ₹4,643 Cr | ₹4,643 Cr -27% | |
| Net Income | ₹199 Cr | ₹369 Cr | ₹317 Cr | ₹427 Cr | ₹369 Cr -46% | |
| Total Assets | ₹8,615 Cr | ₹63,651 Cr | ₹7,055 Cr | ₹8,112 Cr | ₹8,112 Cr +6% | |
| EPS | ₹13.12 | ₹2.82 | ₹7.87 | ₹7.53 | ₹7.53 +74% | |
| Book Value per Share | ₹325.99 | ₹225.92 | ₹120.11 | ₹93.29 | ₹120.11 +171% | |